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Abstract
Matrix metalloproteinases (MMPs) are a family of zinc-dependent proteinases involved in
the regulation of the extracellular signaling and structural matrix environment of cells and
tissues. MMPs are considered as promising targets for the treatment of many diseases.
Therefore, creation of database on the inhibitors of MMP would definitely accelerate the
research activities in this area due to its implication in above-mentioned diseases and asso-
ciated limitations in the first and second generation inhibitors. In this communication, we
report the development of a new MMpI database which provides resourceful information for
all researchers working in this field. It is a web-accessible, unique resource that contains
detailed information on the inhibitors of MMP including small molecules, peptides and MMP
Drug Leads. The database contains entries of ~3000 inhibitors including ~72 MMP Drug
Leads and ~73 peptide based inhibitors. This database provides the detailed molecular and
structural details which are necessary for the drug discovery and development. The MMpI
database contains physical properties, 2D and 3D structures (mol2 and pdb format files) of
inhibitors of MMP. Other data fields are hyperlinked to PubChem, ChEMBL, BindingDB,
DrugBank, PDB, MEROPS and PubMed. The database has extensive searching facility
with MMpI ID, IUPAC name, chemical structure and with the title of research article. The
MMP inhibitors provided in MMpI database are optimized using Python-based Hierarchical
Environment for Integrated Xtallography (Phenix) software. MMpI Database is unique and it
is the only public database that contains and provides the complete information on the inhib-
itors of MMP. Database URL: http://clri.res.in/subramanian/databases/mmpi/index.php.
Introduction
Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases which are implicated
in various diseases. MMPs belong to the metzincin superfamily and are found in plants, verte-
brates and invertebrates [1, 2]. MMPs are important homeostatic protease regulators of extra-
cellular signaling and structural matrix environment of cells and tissues [3]. More than four
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decades ago, Gross and Lapierre [4] discovered MMP (type 1 collagenase). To date, 23 human
MMPs have been reported (Table 1). On the basis of substrate specificity and homology,
MMPs are classified into collagenases, gelatinases, stromelysins, membrane Type-MMP, matri-
lysins, enamelysin, metalloelastase and other MMPs [5, 6].
MMPs are considered as promising targets for the treatment of many diseases such as
arthritis, cancer, atherosclerosis, nephritis, aneurysms, tissue ulcers, and fibrosis [7]. Different
research groups and pharmaceutical companies have made several attempts to develop inhibi-
tors of MMPs. The first generation MMP inhibitors are limited by the poor bioavailability [8]
(e.g., batimastat, D-5410, and Galardin), second generation inhibitors have side-effects [9]
(marimastat) and the third generation inhibitors have no zinc-binding group and depth of the
S1’pocket in most metalloproteases [10]. The effectiveness of the MMP class inhibitors require
(i) functional groups like hydroxamate, carboxylate, thiolate, phosphinyl etc and (ii) capable of
chelating the zinc(II) binding group.
Overall the domain architectures of various MMPs are significantly different. However, the
active site geometries of the catalytic domain of different MMPs are similar. Current
approaches for developing inhibitors consider secondary binding sites (exosites). These are
referred to as regulatory sites, unique exosites have been proposed to be present in all MMPs
[11–13]. Attempts have been made to develop peptide based inhibitors which bind secondary
binding sites (exosites) of MMPs [14].
Numerous compounds have been synthesized by various research groups and also by pharma-
ceutical companies. These compounds have been screened to develop inhibitors of MMPs [15]. To
searchMMPDrug Leads, small molecule inhibitors and peptide based inhibitors, we developed an
online database MMpI (Matrix metalloproteinases Inhibitors). It provides information on physico-
chemical properties, biological activities (IC50 or Ki values) and hyperlinked to other databases.
Overall, MMpI provides MMPDrug Leads, peptide, and small molecule inhibitors information.
Materials and Methods
Source of data
The primary data in the MMpI database are manually extracted from the full text of peer-
reviewed scientific publications in various journals, such as Journal of Medicinal Chemistry,
Bioorganic and Medicinal Chemistry Letters, Organic Letters, Bioconjugate chemistry, European
Journal of Medicinal Chemistry, Bioorganic and Medicinal Chemistry, Bioorganic Chemistry,
The Journal of Biological Chemistry, Anti-Cancer Drugs, Journal of Enzyme Inhibition and
Medicinal Chemistry, Nature Biotechnology, Biochimie, BioChemical Journal, Chemical and
Pharmaceutical Bulletin, Journal of Agricultural and Food Chemistry,Matrix Biology, Biochem-
ical Pharmacology, Bioconjugate Chemistry, Journal of Enzyme Inhibition and Medicinal Chem-
istry. Although, the journals covered are not comprehensive, the selected volumes capture the
high-quality information which is necessary for the development of database. From each
Table 1. Classification of matrix metalloproteinase enzymes.
Collagenases Gelatinases Stromelysins Membrane Type-MMP Matrilysins Enamelysin Others Metalloelastase
MMP-1 MMP-2 MMP-3 MMP-14 MMP-7 MMP-20 MMP-19 MMP-12
MMP-8 MMP-9 MMP-10 MMP-15 MMP-26 MMP-21
MMP-13 MMP-11 MMP-16 MMP-23
MMP-27 MMP-17 MMP-28
MMP-24
MMP-25
doi:10.1371/journal.pone.0159321.t001
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publication the details of the biological activity of tested compounds, target protein and phy-
sico-chemical information are abstracted.
Database architecture and web interface
MMpI is built on Apache HTTP server 2.4 with MySQL 5.6 at the back end, and the PHP 5.5
and JavaScript at the front end. Apache, MySQL, and PHP are preferred as these are open-
source softwares and platform independent.
Results
Description of MMpI database
The MMpI database is openly accessible via a simple, user friendly interface at http://clri.res.
in/subramanian/databases/mmpi/index.php. It is a web-based and platform-independent
Fig 1. A schematic representation of the MMpI Pipeline.
doi:10.1371/journal.pone.0159321.g001
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database with ~3000 inhibitors including ~72 MMP Drug Leads and ~73 peptide based inhibi-
tors. The pipeline of MMpI database is presented in Fig 1 and the home page of the MMpI
database is shown in Fig 2. For example, user can retrieve potential compounds by employing a
keyword search of the database using IUPAC name, derivative type, disease based, MMpI iden-
tifiers, and type of MMP and title of research article of interest.
The browser interface shows the classification of matrix metalloprotease. Using the interface,
the investigator can derive the information (Fig 3). A table view of MMP Drug Lead molecules is
also provided in MMP Drug Leads interface, with structure, MMpI ID, IUPAC name and
Fig 2. Home page of the MMpI database.
doi:10.1371/journal.pone.0159321.g002
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relevant binding protein (Fig 4). Users can go to compound record card to access further infor-
mation, such as structure, bioactivity (IC50 or Ki values), and physico-chemical information.
This Database has a feature to search for a particular compound of interest and to retrieve
information about the compound, or closely related compounds. The structure interface
Fig 3. Interface of the MMpI database browser page.
doi:10.1371/journal.pone.0159321.g003
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Fig 4. Screenshot of the MMpI database showingMMPDrug Leads.
doi:10.1371/journal.pone.0159321.g004
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provides the JME molecular editor drawing tool [16]. It is possible to sketch a structure of
interest. A compound similarity search of the database can be carried out to retrieve inhibitor
which is similar to the input structure (Fig 5).
The interface for peptide inhibitors and triple helical peptide inhibitors show the classifica-
tion of matrix metalloprotease. Based on this, the researchers can view the database and
Fig 5. Choice of sketchers allows the user to draw a structure of interest and search the database for similar compounds.
doi:10.1371/journal.pone.0159321.g005
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retrieve information on the peptide inhibitors (Fig 6). This interface provides the MMpI data-
base unique id for peptide inhibitor, type of MMP, peptide sequence, bioactivity (IC50 or Ki val-
ues) and journal information.
Fig 6. Screenshot of the MMpI database showingMMP peptide inhibitors.
doi:10.1371/journal.pone.0159321.g006
MMpI: Matrix Metalloproteinase Inhibitors
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The download interface allows the investigator to download the MMP inhibitors and MMP
Drug Leads in pdb and mol2 formats (Fig 7). The MMP inhibitor and drug lead files in pdb
and mol2 formats were optimized using Python-based Hierarchical Environment for Inte-
grated Xtallography (Phenix) software [17]. This optimized compound can be used for drug
design, docking or screening studies.
Example
It is expected that researchers look for essential and specific small molecule inhibitors or pep-
tide inhibitors or triple helical peptides for MMP. As an example, to get the structure or analogs
of hydroxamic acid inhibitors of stromelysins, one can search via search box or can sketch
using JME tool which is incorporated in this database (Fig 5). Upon submission, the MMpI
compound search results in a page with suitable structures. Then the researcher can select the
compound of interest and the page will redirect to MMpI, compound record card page. This
page provide further details about MMpI ID, IUPAC name, type of inhibitor and structures
(2D and 3D) visualization in 2D and 3D using Jmol [18]. In addition, it is also possible to down-
load the 3D structure in pdb and mol2 formats. The compound record card also covers bioactivity
(IC50 or Ki values), physico-chemical properties and pharmacological information. In addition,
record card page provides cross-references to other resources like Pubchem [19], ChEMBL [20],
Fig 7. Interface of the MMpI database download page.
doi:10.1371/journal.pone.0159321.g007
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Binding DB [21], DrugBank [22] PDB [23] andMEROPS [24]. Finally the report card contains a
link to the source of the journal from where the information is retrieved (Fig 8A and 8B).
Discussion
MMpI is a web-accessible database that offers quantitative chemical, physical, pharmaceutical
and biological data about thousands of well-studied drug leads, inhibitors and peptide
Fig 8. A screenshot montage of the MMpI database showing. (A) Compound search results. (B) MMP
compound record card.
doi:10.1371/journal.pone.0159321.g008
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inhibitors of MMP. MMpI is primarily focused on providing detailed molecular data needed to
facilitate drug discovery and development. MMpI is unique, not only in the type of data but
also in the level of integration and depth of coverage. In addition to its extensive coverage of
small molecules and drugs, it is the only public database that provides information on the
inhibitors of matrix metalloproteinases. MMpI also supports an extensive array of visualizing,
querying and search options. It is hoped that MMpI will serve as a useful resource to research
community.
Further development
We will try to incorporate the new releases as soon as they will be available in the public
domain.
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